Overview

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Status:
Terminated

Trial end date:
2010-10-01

Target enrollment:

Participant gender:

Summary

To determine if AEG35156 can enhance the combined complete remission (CR) and CR with incomplete platelet recovery (CRp) rate of high-dose cytarabine and idarubicin in AML following failure of a single standard dose cytarabine based frontline induction regimen.

Phase:

Phase 2

Details

Lead Sponsor:

Aegera Therapeutics

Treatments:

Cytarabine
Idarubicin
X-Linked Inhibitor of Apoptosis Protein